Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just ...
A drug being developed by Boehringer Ingelheim for COVID-19 and reinvented as a potential therapy for kidney disease – and has now hit the mark in a phase 2 trial. TRPC6 inhibitor apecotrep (BI 764198 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results